HAPLOTYPE ANALYSIS OF CYP11B2

被引:171
|
作者
WHITE, PC
SLUTSKER, L
机构
[1] Division of Pediatric Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX
关键词
D O I
10.3109/07435809509030459
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymorphisms affecting the synthesis of aldosterone or its regulation may have effects on blood pressure. For example, an autosomal dominant form of human hypertension, glucocorticoid suppressible hyperaldosteronism, is caused by recombination between the genes for aldosterone synthase (CYP11B2) and steroid 11 beta-hydroxylase (CYP11B1), creating a chimeric gene in which the CYP11B1 promoter and CYP11B2-specific coding sequences are juxtaposed. Thus, aldosterone synthesis is improperly regulated. We have begun an analysis of the human CYP11B2 and CYP11B1 genes to see if frequent polymorphisms exist and if they are correlated with differences in blood pressure. We have found frequent polymorphisms in CYP11B2. One in the promoter influences binding of the transcriptional regulatory protein, SF-1. Another is a gene conversion in intron 2 so that most of the intron has a sequence corresponding to CYP11B1. These polymorphisms are in linkage disequilibrium, defining 3 haplotypes. Blacks and whites differ significantly (p < 0.001) in the frequency with which these haplotypes occur. Further studies are required to determine if the observed differences between blacks and whites in blood pressure and in aldosterone levels can be explained in part by these allelic differences in CYP11B2 or by other polymorphisms in linkage disequilibrium on these haplotypes.
引用
收藏
页码:437 / 442
页数:6
相关论文
共 50 条
  • [1] Haplotype analysis of aldosterone synthase gene (CYP11B2) polymorphisms shows association with essential hypertension
    Kumar, NN
    Benjafield, AV
    Lin, RCY
    Wang, WYS
    Stowasser, M
    Morris, BJ
    JOURNAL OF HYPERTENSION, 2003, 21 (07) : 1331 - 1337
  • [2] The human steroid hydroxylases CYP11B1 and CYP11B2
    Bureik, M
    Lisurek, M
    Bernhardt, R
    BIOLOGICAL CHEMISTRY, 2002, 383 (10) : 1537 - 1551
  • [3] Flavone regulation of steroidogenic CYP11B1 and CYP11B2 genes
    Cheng, L. C.
    Lin, J. R.
    Li, L. A.
    TOXICOLOGY LETTERS, 2010, 196 : S57 - S58
  • [4] Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production
    Nicod, M
    Dick, B
    Frey, FJ
    Ferrari, P
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 214 (1-2) : 167 - 174
  • [5] CYP11B2 polymorphisms and cardiovascular risk factors
    Davies, E
    Kenyon, CJ
    JOURNAL OF HYPERTENSION, 2003, 21 (07) : 1249 - 1253
  • [6] CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism
    Mulatero, P
    Schiavone, D
    Fallo, F
    Rabbia, F
    Pilon, C
    Paglieri, C
    Milan, A
    di Cella, SM
    Pascoe, L
    Veglio, F
    JOURNAL OF HYPERTENSION, 2000, 18 : S145 - S146
  • [7] Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production
    Nicod, J
    Dick, B
    Frey, FJ
    Ferrari, P
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 524 - 524
  • [8] Exploring QSAR for CYP11B2 binding affinity and CYP11B2/CYP11B1 selectivity of diverse functional compounds using GFA and G/PLS techniques
    Roy, Partha P.
    Roy, Kunal
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2010, 25 (03) : 354 - 369
  • [9] Disordered CYP11B2 Expression in Primary Aldosteronism
    Gomez-Sanchez, Celso E.
    Kuppusamy, Maniselvan
    Reincke, Martin
    Williams, Tracy Ann
    HORMONE AND METABOLIC RESEARCH, 2017, 49 (12) : 957 - 962
  • [10] Correlations of CYP11B2 gene polymorphisms with eclampsia
    Zou, A-X
    Zhu, F-X
    Jiang, M-X
    Bao, D.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (20) : 10338 - 10345